

INDEPENDENT TRUST FINANCING FACILITY

APPLICATION

Name of Trust:	Homerton University Hospital NHS Foundation Trust			
Amount Proposed:	£10,800,000			
Date of application:	4th December 2013			
Former Strategic Health Authority:	London			
Main Commissioners: (£'000)	(2013)	NHS City and Hackney	£163,164	63.84%
		NHS Croydon	£22,548	8.82%
		NHS London SHA	£12,149	4.75%
		NHS Waltham Forest	£8,085	3.16%
		NHS Haringey	£4,917	1.92%
		Others	£44,712	17.49%
		Total Income	£255,575	100.00%
Existing Loans (Other)	Limit	Drawn	Maturity	Rate
(FTFF)	£655,709	£655,709	N/A	N/A
(FTFF)	£78,853	£78,853	09/03/2015	4.90%
(FTFF)	£603,036	£603,036	07/03/2030	4.90%
(FTFF)	£2,254,652	£2,254,652	07/03/2030	5.60%
Total Existing:	£3,592,249	£3,592,249		
Amounts Proposed:	£10,800,000			
Total:	£14,392,249		25.63%	Tier 1
Purpose of new loan(s):	1) Redevelopment of Pathology Services (£7.9mn) 2) Expansion of Maternity Services (£2.9mn)			
Term of new loan(s):	25 years			
Repayment programme:	Equal instalments of principal			
Interest rate:	National Loan Fund Rate		currently	3.20%
Fees:	Nil			
Security/Covenants	Negative pledge			
Estimated Debt Capacity:				
Long Term (2.5% debt service:revenue)	Tier 1	£56,150,237	Beds:	415
Working Capital (30 days OpEx)		£20,721,197		
Date of Authorisation:	01/04/04	Trust Type: Acute and specialist trust		
Monitor Published Rating:	Finance	3		
	Governance	Green		
Care Quality Commission Rating	Meets all standards			
Reference Cost Index (2010/11)	99	(MFF adjusted)	110	(Non-adjusted)
Ratios:	Required (Tier 1)		Projected (max)	
Minimum dividend cover	>1x		3.60	
Minimum interest cover	>3x		22.77	
Minimum debt service cover	>2x		9.85	
Maximum debt service / net revenue	<2.5%		0.65%	
Debt / net assets			12%	

Homerton University Hospital NHS Foundation Trust

Introduction

Homerton has requested a loan for £10,000,000 to cover two planned developments:

1) Redevelopment of Pathology Services (£7.9mn)

The core objective of this development is the delivery of an accredited pathology service to sustain and support growth in the Trust's clinical services and provide a service for GP pathology activity as there is a significant risk that if appropriate redevelopment and expansion of space is not provided, the laboratory service will fail as maximum capacity is reached in 2015/16.

The Trust currently provides a core diagnostic pathology service for biochemistry, microbiology, haematology and blood transfusion services 24 hours a day 7 days a week. Delivery of a 24/7 service is an essential requirement to support A&E, emergency admissions, theatres, maternity, ITU and SCBU. Growth in demand on all diagnostic services has shown an upward trend year on year over recent years.

The existing pathology laboratories are in any case over 20 years old and no longer fit for purpose and at risk of being non-compliant with CPA, MHRA, Health & Safety and Fire Regulations. Previous inspections have highlighted that space is at a premium for the level of service provided, and the existing configuration of the laboratories on two floors does not allow any further service modernisation, (automation and integration) presenting a serious challenge in terms of the future of the laboratories.

Four options have been considered:

- a) Do nothing;
- b) Outsource;
- c) Split hot/cold on a hub and spoke model, outsourcing non-urgent;
- d) Redevelop / Refurbish:

The preferred option is a redevelopment of the existing service provision as this retains the current level of service with scope for expansion and, in part, is also based upon economic returns predicated by retention of the GP services. Redevelopment is a more efficient option than refurbishment as it does not incur additional costs of continuing to provide the service during the build, and allows for the release of some redundant space for clinical use.

2) Expansion of Maternity Services (£2.9mn)

The Homerton's maternity service has expanded significantly over recent years not least as a consequence of the re-structuring of maternity provision across North East London as in October 2012 the Trust started to take bookings from 15 GP practices in Waltham Forest as part of the strategy to transfer 800 births from Whipps Cross. Achieving 800 additional births per year was based on an assumption that an average of 70% of women from the 15 GP

practices would book to have their baby at Homerton. Since the start of 2013, bookings from the Waltham Forest area, and beyond, have been above the planned rate and the Trust is currently projecting in the region of 6240 births for 2013/14, which is a total increase of 1040 births per annum.

In response to this increase in activity a business case was agreed, in February 2013, to fund 7 additional post natal beds (on the vacant 2012 ward) and 4 additional special care cots (in the neonatal treatment room). This additional capacity has ensured that the Trust has adequate post natal and special care capacity for up to 6240 births per annum but no physical flexibility to grow beyond this level.

The total additional income from the additional births comes to £4.44m which gives a surplus of £195,000 after service costs and overheads are accounted for.

The solutions to the increased activity were put in place as part of a rapid response to safety concerns at Queens and were always intended as a temporary measure. Although tolerable for a short period of time, having inpatient post natal care split across two areas is inefficient and creates a number of logistical and patient care issues for the service, including:

- In emergency situations staff on 2012 ward have to call on staff from Delivery Suite for support;
- With patients split across two separate areas it is difficult to achieve the optimum staff to patient ratio;
- The lack of a full reception function on 2012 ward makes it difficult for staff to manage visitors adequately; and
- Organising cover so that staff on 2012 Ward can take their breaks is difficult given the small and relatively isolated workforce.

Furthermore, the additional cots created on the neonatal unit do not meet the current building and infection control standards and their location on the unit means that they can only be used for babies requiring the lowest level of care. Accommodating the additional costs also required the treatment room to be relocated to a much smaller space that is not adequate for a busy level 3 unit.

Whilst the steps taken to accommodate the additional flow of births were reasonable given the regional context in late 2012 and whilst they do not constitute a material risk to patient safety they are clearly sub-optimal and are not accepted by the Trust as viable long-term solutions.

When the Trust commissioned its new Delivery Unit a few years ago a second floor was built but kept vacant. In order to develop this space it is now proposed that the fetal medicine and antenatal ultrasound services are transferred to the second floor. The area released is adjacent to the Trust's post natal ward and will therefore facilitate the expansion of both post natal beds and neonatal cots directly addressing – in a sustainable manner – the growth and quality drivers outlined above.

The proposed scheme comprises of two elements, the access core and the second floor fit out. The costs of the access core (lift and stair access) are estimated at £1.1m (approximately 35% of the overall cost of the scheme). It is worth noting that the Trust would

have to incur this cost to bring the second floor in to use to provide any clinical services. The cost of fitting out the second floor for the delivery of maternity services is estimated at £2m.

Background

Homerton provides hospital and community services for Hackney, the City and the surrounding communities, and a bespoke range of specialist services for a wider population from the Homerton Hospital; Mary Seacole Continuing Care Nursing Home; and community and home care services across Hackney and the City.

The main hospital, which opened in 1986 is based on one site whilst the community service provision, assumed in 2011/12, operates from a total of 73 sites of varying sizes and levels of occupancy across the London Borough of Hackney.

The Trust was a designated Olympic Hospital for the Games in 2012 assessing and treating over 70 members of the Olympic Family with the majority of specialties and services being involved at some point during the period of both Games, and receiving Olympic legacy sponsorship from General Electric (GE) enabling it to equip its specialist neonatal services with the most sophisticated equipment available.

Recent performance

Homerton has performed strongly in recent years, achieving an I&E surplus of £3.8m for 2012/13 (before impairments of £3.5m), which exceeding the planned for surplus of £2.6m. The main source of income for the Trust is contracts with commissioners in respect of health care services, the Trust's main commissioner being City and Hackney Primary Care Trust.

The I&E surplus was achieved from additional income generated from higher than expected levels of day case, elective and outpatient activity. Activity and income for neonatal and the special care baby unit also exceeded plans.

Income from non-patient activity was also above plan for education and training and for services provided to other organisations. Expenditure was above planned levels mainly due to the costs of delivering increased activity.

The Trust achieved £9.2m of savings during the year as part of its QIPP agenda. Projects included staffing and skill mix reviews, more efficient use of our capacity and procurement initiatives to secure better prices and contractual terms from suppliers.

The Trust's liquidity position remained strong, partly due to on-going slippage in the capital programme and also achieving a greater than planned surplus. Capital expenditure totalled approximately £9.2m, including: £3.1m on medical equipment; £2.1m related to the expansion of the endoscopy suite, and £1.3m on an additional theatre.

The Trust achieved a financial risk rating score of 4 from Monitor which was better than planned.

The Trust remains in a relatively strong financial position having achieved or exceeded its planned level of surplus in recent years. It is also projecting surpluses in each of the next three years.

Detailed Financial Summary £m	2012/13 Actual	2013/14 Plan	2014/15 Plan	2015/16 Plan
Acute	174.6	182.7	186.9	187.3
Community	46.8	46.1	44.9	43.9
Other operating revenues	34.2	27.3	25.5	25.3
Total Operating Revenue	255.6	256.1	257.3	256.5
Employee expenses	(167.2)	(173.5)	(175.5)	(173.8)
Drugs expenses	(12.0)	(12.4)	(13.0)	(13.7)
Other operating expenses	(63.6)	(57.9)	(55.8)	(55.8)
Total Operating Expenses	(242.8)	(243.8)	(244.3)	(243.3)
Net interest payable/receivable	-	(0.2)	(0.2)	(0.2)
Depreciation and amortisation	(5.7)	(6.3)	(6.6)	(6.7)
PDC Dividend	(3.3)	(3.2)	(3.6)	(3.5)
Total Expenses	(251.8)	(253.5)	(254.7)	(253.7)
Net Surplus (before impairments)	3.8	2.6	2.6	2.8
Forecast Financial Risk Rating	4	3 tbc*	3 tbc*	3 tbc*

Plans are in place to meet an £11.2m CIP requirement for 2013/14 (4.5% of forecast income). For 2014/15 and 2015/16 the efficiency savings required to achieve a target 1% surplus are estimated at a similar level.

Capital Expenditure Plans

The main capital schemes and estimated costs for the next three years are shown in the table below, along with associated internal funding sources.

PLANNED CAPITAL PROGRAMME	2013/14 £m	2014/15 £m	2015/16 £m
Service Developments	2.4	3.1	3.2
Estate Schemes	7.4	1.5	1.5
Medical Equipment	4.3	4.0	4.0
Other	0.9	1.4	1.3
Total Programme	15.0	10.0	10.0
Source of funds			
Depreciation	5.7	6.2	6.2
Brought forward from prior year	4.5	-	-
Use of cash reserves/	4.8	3.8	3.8
Total funding	15.0	10.0	10.0

The plan includes a major development in relation to boiler replacement (approximately £5m included within Estates schemes in 2013/14) programme which is due to complete in December 2013. Whilst the Trust has applied for a contribution towards the funding of the boiler replacement project via the Department of Health's sustainability initiative for

approximately £3m, the plan does not assume any funding from this source and the project is not contingent on it.

The pathology redevelopment is included in the plan (approximately £1m; £6m; and £1m included within service developments in 2013/14, 2014/15, and 2015/6, respectively).

Recommendation

Historically the Trust has funded its capital plan solely from internally generated resources. The capital plan for the next 3 years was presented on a similar basis but with the proviso that if additional discretionary spend was considered appropriate the Trust would look at external sources of funding as well. With a planned programme over the next three years in excess of depreciation and a number of significant commitments such as the boiler, service developments and equipment replacement (e.g. MRI scanner), Homerton feels it appropriate reduce the reliance on continued surpluses by borrowing against part of the programme.

Trust performance over the past three years has been consistently strong, although the integration of community services and the Olympics have introduced some variances to the final results. The Trust continues to plan to deliver surpluses and this does not seem unreasonable.

The loan is easily affordable, and current levels of debt not extreme. This loan is recommended for approval.

NR/02.12.2013

INCOME STATEMENT	2010/11	2011/12	2012/13
	£'000	£'000	£'000
Operating Income from continuing operations	190,871	243,677	255,575
Operating Expenses of continuing operations	(187,794)	(235,066)	(252,108)
OPERATING SURPLUS / (DEFICIT)	3,077	8,610	3,467
FINANCE COSTS			
Finance income	113	145	206
Finance expense - financial liabilities	(198)	(186)	(174)
Finance expense - unwinding of discount on provisions	(22)	(19)	(16)
PDC Dividends payable	(3,491)	(3,296)	(3,184)
NET FINANCE COSTS	(3,598)	(3,357)	(3,167)
Share of Profit / (Loss) of Associates/Joint Ventures accounted for using the equity method	0	0	0
Gain/(loss) from transfer by absorption	0	0	0
Movement in fair value of investment property and other investments	0	0	0
Corporation tax expense	0	0	0
Surplus/(Deficit) from continuing operations	(521)	5,253	300
Surplus/(deficit) of discontinued operations and the gain/(loss) on disposal of discontinued operations	0	0	0
SURPLUS/(DEFICIT) FOR THE YEAR	(521)	5,253	300
Other comprehensive income			
Impairments	(519)	(2,254)	(1,711)
Revaluations	1,897	57	1,956
Transfer to retained earnings on disposal of assets	14	1	0
Movements arising from classifying non current assets as Assets Held for Sale	0	0	0
Other recognised gains and losses	0	0	0
Actuarial gains/(losses) on defined benefit pension schemes	0	0	0
Other reserve movements	0	0	0
TOTAL COMPREHENSIVE INCOME / (EXPENSE) FOR THE PERIOD	872	3,057	544
Prior period adjustments	0	0	0
Merger adjustments	0	0	0
TOTAL COMPREHENSIVE INCOME / (EXPENSE) FOR THE YEAR	872	3,057	544

BALANCE SHEET	2010/11	2011/12	2012/13
	£'000	£'000	£'000
Non-current assets			
Intangible assets	742	641	431
Property, plant and equipment	117,617	115,121	115,658
Investment Property	0	0	0
Investments in associates (and joined controlled operations)	0	0	0
Other Investments	0	0	0
Trade and other receivables	0	0	0
Other financial assets	0	0	0
Other assets	0	0	0
Total non-current assets	118,359	115,763	116,089
Current assets			
Inventories	1,025	1,121	1,388
Trade and other receivables	10,465	13,455	12,626
Other financial assets	25	0	0
Non-current assets for sale and assets in disposal groups	0	0	0
Cash and cash equivalents	17,088	30,556	29,622
Total current assets	28,603	45,133	43,636
Current liabilities			
Trade and other payables	(16,523)	(23,389)	(21,728)
Borrowings	(257)	(257)	(257)
Other financial liabilities	0	0	0
Provisions	(638)	(1,685)	(1,005)
Other liabilities	(3,104)	(5,403)	(5,040)
Liabilities in disposal groups	0	0	0
Total current liabilities	(20,522)	(30,733)	(28,030)
Total assets less current liabilities	126,440	130,163	131,695
Non-current liabilities			
Trade and other payables	0	0	0
Borrowings	(4,051)	(3,795)	(3,538)
Other financial liabilities	0	0	0
Provisions	(644)	(641)	(1,109)
Other liabilities	0	0	0
Total non-current liabilities	(4,695)	(4,436)	(4,647)
Total assets employed	121,745	125,727	127,048
Financed by			
Minority Interest	0	0	0
Public Dividend Capital	83,175	84,100	84,877
Revaluation reserve	23,142	20,859	21,092
Available for sale investments reserve	0	0	0
Other reserves	0	0	0
Merger reserve	0	0	0
Income and expenditure reserve	15,428	20,768	21,078
Total taxpayers' and others' equity	121,745	125,727	127,048

CASHFLOW STATEMENT	2010/11	2011/12	2012/13
	£'000	£'000	£'000
Operating surplus/(deficit) from continuing operations	3,077	8,610	3,467
Operating surplus/(deficit) of discontinued operations	0	0	0
Operating surplus/(deficit)	3,077	8,610	3,467
Depreciation and amortisation	5,763	6,011	5,723
Impairments	5,172	916	3,529
Reversals of impairments	0	0	0
EBITDA	14,012	15,537	12,719
(Gain)/Loss on disposal	0	2	0
Non-cash donations/grants credited to income	0	0	0
Interest accrued and not paid	0	0	0
Dividends accrued and not paid or received	0	0	0
Amortisation of government grants	0	0	0
Amortisation of PFI credit	0	0	0
(Increase)/Decrease in Trade and Other Receivables	493	(2,990)	830
(Increase)/Decrease in Other Assets	0	0	0
(Increase)/Decrease in Inventories	(138)	(96)	(267)
Increase/(Decrease) in Trade and Other Payables	1,992	6,864	(1,661)
Increase/(Decrease) in Other Liabilities	(3,196)	2,299	(305)
Increase/(Decrease) in Provisions	384	1,043	(211)
Tax (paid) / received	426	0	0
Movements in operating cash flow of discontinued operations	0	0	0
Movements in operating cash flow in respect of Transforming Community Services transaction	(274)	0	0
Other movements in operating cash flows	(2,314)	(1,152)	0
NET CASH GENERATED FROM/(USED IN) OPERATIONS	11,385	21,507	11,104
Cash flows from investing activities			
Interest received	113	145	206
Purchase of financial assets	0	0	0
Sales of financial assets	0	0	0
Purchase of intangible assets	(34)	(323)	(68)
Sales of intangible assets	0	0	0
Purchase of Property, Plant and Equipment	(6,814)	(5,134)	(9,359)
Sales of Property, Plant and Equipment	58	0	0
Cash flows attributable to investing activities of discontinued operations	0	0	0
Cash from acquisitions of business units and subsidiaries	0	0	0
Cash from (disposals) of business units and subsidiaries	0	0	0
Net cash generated from/(used in) investing activities	(6,677)	(5,312)	(9,220)
Cash flows from financing activities			
Public dividend capital received	0	925	777
Public dividend capital repaid	0	0	0
Loans received from the Foundation Trust Financing Facility	0	0	0
Loans received from the Department of Health	0	0	0
Other loans received	0	0	0
Loans repaid to the Foundation Trust Financing Facility	0	(226)	(226)
Loans repaid to the Department of Health	(226)	0	0
Other loans repaid	(31)	(31)	(31)
Capital element of finance lease rental payments	0	0	0
Other capital receipts	0	0	0
Capital element of Private Finance Initiative Obligations	0	0	0
Interest paid	(198)	(186)	(174)
Interest element of finance lease	0	0	0
Interest element of Private Finance Initiative obligations	0	0	0
PDC Dividend paid	(3,700)	(3,208)	(3,165)
Cash flows from (used in) other financing activities	0	0	0
Net cash generated from/(used in) financing activities	(4,155)	(2,726)	(2,819)
Increase/(decrease) in cash and cash equivalents	553	13,468	(935)
Cash and Cash equivalents at 1 April	16,535	17,088	30,556
Cash and Cash equivalents at start of period for new FTs	0	0	0
Cash and Cash equivalents changes due to transfers by absorption	0	0	0
Cash and Cash equivalents at 31 March and 31 March	17,088	30,556	29,622

RATIOS	2010/11	2011/12	2012/13
	£'000	£'000	£'000
EBITDA Margin	7.34%	6.38%	4.98%
Surplus Margin	2.44%	2.53%	1.50%
Average Return on Assets		4.99%	3.03%
Current Ratio	139%	147%	156%
Cashflow Ratio (Op Cash / Depreciation + Dividend)	151%	167%	143%
Capex Ratio (Capex / Depreciation)	116%	88%	161%
Gearing (LT Liabs / Net Assets)	4%	4%	4%
Liquidity (Days OpCosts)	14	21	21
Debt Coverage Ratio	3.37	4.26	3.54
Liquidity Rating	4	4	4
Debt Coverage Rating	4	4	4
Overall Rating	4	4	4

Homerton University Hospital NHS Foundation Trust

	2010/11 £'000	2011/12 £'000	2012/13 £'000	2010/11 £'000	2011/12 £'000	2012/13 £'000	
Operating Costs as % of Revenues							
Total Revenues	190,871	243,677	255,575				All FTs
Employee Expenses	122,487	158,815	167,460	64.17%	65.17%	65.52%	62.12%
Redundancy & Early Retirement	-	-	19	0.00%	0.00%	0.01%	0.31%
R & D	149	140	31	0.08%	0.06%	0.01%	0.53%
Pay Costs	122,636	158,955	167,510	64.25%	65.23%	65.54%	62.96%
Services from NHS Bodies	-	826	876	0.00%	0.34%	0.34%	1.62%
Purchase of healthcare from non NHS bodies	163	377	329	0.09%	0.15%	0.13%	0.78%
Purchase of External Services	163	1,203	1,205	0.09%	0.49%	0.47%	2.40%
Supplies and services - clinical (excluding drug costs)	11,263	14,741	17,005	5.90%	6.05%	6.65%	7.55%
Supplies and services - general	1,469	1,765	1,711	0.77%	0.72%	0.67%	1.75%
Inventories consumed (excluding drugs)	-	-	-	0.00%	0.00%	0.00%	0.71%
Drug Costs	10,748	11,049	12,941	5.63%	4.53%	5.06%	7.25%
Supplies and Services	23,480	27,555	31,657	12.30%	11.31%	12.39%	17.26%
Establishment	2,399	3,054	3,619	1.26%	1.25%	1.42%	1.38%
Premises	19,897	27,644	28,557	10.42%	11.34%	11.17%	4.58%
Rentals under operating leases	-	1,004	424	0.00%	0.41%	0.17%	0.80%
Loss on Disposal	65	2	-	0.03%	0.00%	0.00%	0.06%
Premises	22,361	31,703	32,600	11.72%	13.01%	12.76%	6.82%
Consultancy costs	1,220	1,038	1,390	0.64%	0.43%	0.54%	0.50%
Professional Fees	53	215	269	0.03%	0.09%	0.11%	0.18%
Clinical negligence	4,236	4,683	5,203	2.22%	1.92%	2.04%	1.27%
Professional Costs	5,509	5,936	6,863	2.89%	2.44%	2.69%	1.95%
Provisions & Write Downs	741	52.3	600.37	0.39%	0.02%	0.23%	0.11%
Other	1,968	2,736	2,421	1.03%	1.12%	0.95%	0.00%
Provisions and Other	2,709	2,788	3,021	1.42%	1.14%	1.18%	0.11%
Total Cash OpCosts	176,858	228,139	242,856	92.66%	93.62%	95.02%	93.74%
EBITDA	14,013	15,537	12,719	7.34%	6.38%	4.98%	6.26%
Total Revenues	190,871	243,677	255,575	100.00%	100.00%	100.00%	100.00%
Depreciation	5,251	5,589	5,445	2.75%	2.29%	2.13%	2.70%
Amortisation	513	423	278	0.27%	0.17%	0.11%	0.14%
Impairments	5,172	916	3,529	2.71%	0.38%	1.38%	1.78%
Net Non-Cash	10,936	6,927	9,252	5.73%	2.84%	3.62%	4.62%
Operating Surplus / Deficit before Financing Costs	3,077	8,610	3,467	1.61%	3.53%	1.36%	

Planned Quarterly Income Statement for HOMERTON

These figures should change in line with your assumptions for future years

Operating

NHS Clinical Revenue

NHS Ambulance activity Income, Total

NHS Community activity revenue

Block Contract revenue, community based activity

NHS Community activity revenue, Total

NHS Mental Health activity Income, Total

NHS Acute Activity Income, Total

Sub-total NHS Clinical Revenue

Contract penalties or adjustments not included above

NHS Clinical Revenue, Total

Non Mandatory/Non protected revenue

Private patient revenue

Other Non Mandatory/Non protected clinical revenue

Non Mandatory/Non protected revenue, Total

Other Operating revenue, Total

Operating Revenue, IFRS, Total

Operating Expenses

Raw Materials and Consumables Used

Raw Materials and Consumables Used, Total

Ambulance trusts vehicle operating expenses, Total

Cost of Secondary Commissioning of mandatory services

Employee Expenses [was "Pay"]

Employee expenses, permanent staff

Employee expenses, agency & contract staff

Employee Expenses, Total

Research & Development expense

Education and training expense

Consultancy expense

Misc. other Operating expenses

(Increase)/decrease in Provisions, Current and Non-Current, net

(Increase)/decrease in Impairment of receivables, Current and Non-Current, net

PFI operating expenses

PFI unitary payment

IFRIC12 revenue/(expense) adjustment

Other PFI expenses

PFI operating expenses, total

Operating Expenses within EBITDA, Total

Depreciation and Amortisation

Depreciation and Amortisation - purchased/constructed assets

Depreciation and Amortisation - donated/granted assets

Depreciation and Amortisation - owned assets

Depreciation and Amortisation - assets held under finance leases

Depreciation and Amortisation - PFI assets

Depreciation and Amortisation, Total

Impairment (Losses) / Reversals net - purchased/constructed assets

Impairment (Losses) / Reversals net - donated/granted assets

Impairment (Losses) / Reversals net (on non-PFI assets)

Impairment (Losses)/ Reversals net on PFI assets

Restructuring Costs

Operating Expenses excluded from EBITDA, Total

Operating Expenses IFRS, Total

Surplus (Deficit) from Operations

Non Operating

Non-Operating income

Finance Income [for non-financial activities], Total

Other Non-Operating income, Total

Non-Operating income, Total

Non-Operating expenses

Finance Costs [for non-financial activities], Total

Other Non-Operating expenses, Total

Non-Operating expenses, Total

Surplus (Deficit) before Tax

Income Tax (expense)/ refund

Surplus (Deficit) After Tax

Profit/(loss) from discontinued Operations, Net of Tax

Surplus (Deficit) After Tax from Continuing Operations

	Actual for	Plan for	Plan for	Plan for
	Year ending	Year ending	Year ending	Year ending
	31-Mar-13	31-Mar-14	31-Mar-15	31-Mar-16
NHS Clinical Revenue				
NHS Ambulance activity Income, Total	0.000	0.000	0.000	0.000
NHS Community activity revenue				
Block Contract revenue, community based activity	46.810	46.060	44.862	43.863
NHS Community activity revenue, Total	46.810	46.060	44.862	43.863
NHS Mental Health activity Income, Total	0.000	0.000	0.000	0.000
NHS Acute Activity Income, Total	174.617	182.723	186.872	187.263
Sub-total NHS Clinical Revenue	221.427	228.783	231.734	231.127
Contract penalties or adjustments not included above		0.000		
NHS Clinical Revenue, Total	221.427	228.783	231.734	231.127
Non Mandatory/Non protected revenue				
Private patient revenue	0.549	0.600	0.600	0.600
Other Non Mandatory/Non protected clinical revenue	0.000	0.000		
Non Mandatory/Non protected revenue, Total	0.549	0.600	0.600	0.600
Other Operating revenue, Total	33.599	26.749	24.930	24.730
Operating Revenue, IFRS, Total	255.575	256.132	257.265	256.457
Operating Expenses				
Raw Materials and Consumables Used				
Raw Materials and Consumables Used, Total	(72.454)	(68.614)	(68.861)	(69.515)
Ambulance trusts vehicle operating expenses, Total	0.000	0.000	0.000	0.000
Cost of Secondary Commissioning of mandatory services		0.000		
Employee Expenses [was "Pay"]				
Employee expenses, permanent staff	(147.328)	(167.454)	(169.361)	(167.737)
Employee expenses, agency & contract staff	(19.889)	(6.094)	(6.094)	(6.094)
Employee Expenses, Total	(167.217)	(173.548)	(175.455)	(173.831)
Research & Development expense	(0.293)	(0.095)		
Education and training expense	(0.996)	(0.976)		
Consultancy expense	(1.261)	(0.568)		
Misc. other Operating expenses		0.000	0.000	0.000
(Increase)/decrease in Provisions, Current and Non-Current, net		0.000		
(Increase)/decrease in Impairment of receivables, Current and Non-Current, net	(0.547)	0.000		
PFI operating expenses				
PFI unitary payment		0.000		
IFRIC12 revenue/(expense) adjustment		0.000		
Other PFI expenses		0.000		
PFI operating expenses, total	0.000	0.000	0.000	0.000
Operating Expenses within EBITDA, Total	(242.768)	(243.801)	(244.317)	(243.346)
Depreciation and Amortisation				
Depreciation and Amortisation - purchased/constructed assets	(5.723)	(6.322)	(6.619)	(6.663)
Depreciation and Amortisation - donated/granted assets	0.000	0.000		
Depreciation and Amortisation - owned assets	(5.723)	(6.322)	(6.619)	(6.663)
Depreciation and Amortisation - assets held under finance leases	0.000	0.000		
Depreciation and Amortisation - PFI assets	0.000	0.000		
Depreciation and Amortisation, Total	(5.723)	(6.322)	(6.619)	(6.663)
Impairment (Losses) / Reversals net - purchased/constructed assets	(3.529)	(0.800)	(1.200)	(1.200)
Impairment (Losses) / Reversals net - donated/granted assets	0.000	0.000		
Impairment (Losses) / Reversals net (on non-PFI assets)	(3.529)	(0.800)	(1.200)	(1.200)
Impairment (Losses)/ Reversals net on PFI assets	0.000	0.000		
Restructuring Costs	0.000	0.000		
Operating Expenses excluded from EBITDA, Total	(9.252)	(7.122)	(7.819)	(7.863)
Operating Expenses IFRS, Total	(252.020)	(250.923)	(252.136)	(251.209)
Surplus (Deficit) from Operations	3.555	5.208	5.129	5.248
Non-Operating income				
Finance Income [for non-financial activities], Total	0.206	0.000	0.000	0.000
Other Non-Operating income, Total	(0.088)	0.000	0.000	0.000
Non-Operating income, Total	0.118	0.000	0.000	0.000
Non-Operating expenses				
Finance Costs [for non-financial activities], Total	(3.374)	(3.386)	(3.756)	(3.660)
Other Non-Operating expenses, Total	0.000	0.000	0.000	0.000
Non-Operating expenses, Total	(3.374)	(3.386)	(3.756)	(3.660)
Surplus (Deficit) before Tax	0.299	1.823	1.373	1.588
Income Tax (expense)/ refund		0.000		
Surplus (Deficit) After Tax	0.299	1.823	1.373	1.588
Profit/(loss) from discontinued Operations, Net of Tax		0.000		
Surplus (Deficit) After Tax from Continuing Operations	0.299	1.823	1.373	1.588

Planned Quarterly Income Statement for HOMERTON

These figures should change in line with your assumptions for future years

Operating

Elements of Comprehensive Income

Share of comprehensive income from associates and joint ventures

Revaluation gains/(losses) of donated/granted assets straight to reval reserve

Revaluation gains/(losses) of purchased/constructed assets straight to reval reserve

Revaluation gains/(losses) straight to revaluation reserve

(Impairments)/reversals of purchased/constructed assets straight to reval reserve

(Impairments)/reversals of donated/granted assets straight to reval reserve

Impairments/(reversals) straight to revaluation reserve

Fair Value gains/(losses) straight to reserves

Additions/(reduction) in "Other reserves"

Other recognised gains and losses

Actuarial gains/(losses) on defined benefit pension schemes

Elements of Comprehensive Income, Total

Total Comprehensive Surplus/(Deficit)

Memorandum lines

Total Revenue

Total Expenses

Total Operating Revenue for EBITDA

Total Operating Expenses for EBITDA

EBITDA (for FRR calculation)

Operating Surplus (Deficit)

Surplus (Deficit) After Tax (for FRR calculation)

Return After Financing (for FRR calculation)

OTHER INFORMATION

Revenue Generation Programmes

Revenue Generation, net

Cost Improvement Programmes

Pay Expense savings CIP recurrent

Pay Expense savings CIP non-recurrent

Pay Expense savings CIP, TOTAL

Drugs expense savings CIP recurrent

Drugs expense savings CIP non-recurrent

Drugs expense savings CIP, TOTAL

Clinical Supplies expense savings CIP recurrent

Clinical Supplies expense savings CIP non-recurrent

Clinical Supplies expense savings CIP

Non-clinical Supplies expense savings CIP recurrent

Non-clinical Supplies expense savings CIP non-recurrent

Non-clinical Supplies expense savings CIP

Misc. Other Operating Expenses CIP recurrent

Misc. Other Operating Expenses CIP non-recurrent

Misc. Other Operating Expenses CIP

Other expense savings CIP, recurrent

Other expense savings CIP non-recurrent

Other expense savings CIP

Cost Improvement Programmes, Total

MEMORANDUM lines

Private Patient Income, YTD, Total

Proxy for Patient Related Income, YTD, Total

Private Patient Income, YTD, %

PBC Calculations

Revenue available for debt service

Planned debt Interest expense (excl Bridging loans)

PDC dividend payable

Revenue

CIP% of Op.Exp. less PFI Exp.

Actual for	Plan for	Plan for	Plan for
Year ending	Year ending	Year ending	Year ending
31-Mar-13	31-Mar-14	31-Mar-15	31-Mar-16
	0.000		
1.956	0.000		
	0.000		
1.956	0.000	0.000	0.000
(1.722)	(1.200)	(2.100)	(2.100)
	0.000		
(1.722)	(1.200)	(2.100)	(2.100)
	0.000		
	0.000		
	0.000		
	0.000		
0.234	(1.200)	(2.100)	(2.100)
0.533	0.623	(0.727)	(0.512)

255.693	256.132	257.265	256.457
(255.395)	(254.309)	(255.892)	(254.869)
255.575	256.132	257.265	256.457
(242.768)	(243.801)	(244.317)	(243.346)
12.807	12.330	12.948	13.111
3.555	5.208	5.129	5.248
0.299	1.823	1.373	1.588
3.916	2.623	2.573	2.788

1.948	2.145	0.000	0.000
2.113	4.862	6.224	6.286
	0.000		
2.113	4.862	6.224	6.286
0.161	0.271	0.000	0.000
	0.000		
0.161	0.271	0.000	0.000
0.762	1.503	2.457	2.200
	0.000		
0.762	1.503	2.457	2.200
0.636	1.533	1.319	1.514
0.234	0.000		
0.870	1.533	1.319	1.514
	0.000		
	0.000		
0.000	0.000	0.000	0.000
	0.000		
	0.000		
0.000	0.000	0.000	0.000
3.906	8.169	10.000	10.000

0.549	0.600	0.600	0.600
221.976	229.383	232.334	231.727
0.2%	0.3%	0.3%	0.3%

13.013	12.330	12.948	13.111
-0.174	-0.174	-0.174	-0.174
-3.184	-3.212	-3.582	-3.486
255.575	256.132	257.265	256.457
1.6%	3.2%	3.9%	1.5%

Planned Quarterly Statement of Position for HOMERTON

These figures should change in line with your assumptions for future years

	Actual at 31-Mar-13	Plan for 31-Mar-14	Plan for 31-Mar-15	Plan for 31-Mar-16
Assets				
Assets, Non-Current				
Intangible Assets, Net, Donated or granted		0.000		
Intangible Assets, Net, Purchased or created	0.431	0.476	0.499	0.492
Intangible Assets, Net	0.431	0.476	0.499	0.492
Property, Plant and Equipment, Net, Donated or granted		0.000		
Property, Plant and Equipment, Net, Purchased or constructed	115.658	125.524	125.636	125.681
Property, Plant and Equipment, Net	115.658	125.524	125.636	125.681
On balance sheet PFI assets, Non-Current, Total	0.000	0.000	0.000	0.000
Investment Property		0.000		
Investments, Non-Current, Total	0.000	0.000	0.000	0.000
Deferred Tax Assets		0.000		
Trade and Other Receivables, Net, Non-Current, Total	0.000	0.000	0.000	0.000
Prepayments, Non-Current				
Prepayments, Non-current, PFI related (eg lifecycle assets)		0.000		
Prepayments, Non-current, non-PFI related		0.000		
Prepayments, Non-Current	0.000	0.000	0.000	0.000
Other Financial Assets, Non-Current, Total	0.000	0.000	0.000	0.000
Off balance sheet PFI assets, Non-Current, Total	0.000	0.000	0.000	0.000
Other Assets, Non-Current, Total	0.000	0.000	0.000	0.000
Assets, Non-Current, Total	116.089	126.001	126.136	126.173
Assets, Current				
Inventories	1.388	1.582	1.500	1.500
Current Tax Receivables		0.000		
Trade and Other Receivables, Net, Current, Total	8.164	7.007	6.250	6.557
Other Financial Assets, Current, Total	3.932	3.800	3.860	3.900
Prepayments, Current, Total	0.530	0.560	0.540	0.543
Cash and Cash Equivalents, Total	29.622	22.870	22.312	20.757
Other Assets, Current, Total	0.000	0.000	0.000	0.000
Assets, Current, Total	43.636	35.820	34.462	33.257
ASSETS, TOTAL	159.725	161.821	160.598	159.429
Liabilities				
Liabilities, Current				
Interest-Bearing Borrowings, Current, Total	(0.225)	(0.225)	(0.225)	(0.225)
Non-Interest-Bearing Borrowings, Current	(0.031)	(0.031)	(0.031)	(0.031)
Deferred Income, Current	(5.040)	(3.780)	(3.700)	(3.650)
Deferred Grant Income, Current	0.000	0.000		
Provisions, Current	(1.006)	(0.402)	(0.500)	(0.450)
Post-Employment Benefit Obligation, Current	0.000	0.000		
Current Tax Payables	(5.586)	(5.586)	(5.580)	(5.500)
Trade and Other Payables, Current, Total	(9.347)	(9.578)	(9.352)	(9.152)
Other Financial Liabilities, Current, Total	(6.796)	(6.883)	(6.883)	(6.883)
Other Liabilities, Current, Total	0.000	0.000	0.000	0.000
Liabilities, Current, Total	(28.031)	(26.485)	(26.271)	(25.891)
NET CURRENT ASSETS (LIABILITIES)	15.605	9.335	8.191	7.366
Liabilities, Non-Current				
Interest-Bearing Borrowings, Non-Current, Total	(2.824)	(2.599)	(2.374)	(2.149)
Non-Interest-Bearing Borrowings, Non-Current	(0.715)	(0.684)	(0.653)	(0.622)
Deferred Income, Non-Current		0.000		
Deferred Grant Income, Non-Current		0.000		
Provisions, Non-Current	(1.109)	(1.076)	(1.050)	(1.030)
Post-Employment Benefit Obligation, Non-Current		0.000		
Deferred Tax liabilities		0.000		
Trade and Other Payables, Non-Current, Total	0.000	0.000	0.000	0.000
Other Financial Liabilities, Non-Current, Total	0.000	0.000	0.000	0.000
Other Liabilities, Non-Current, Total	0.000	0.000	0.000	0.000
Liabilities, Non-Current, Total	(4.648)	(4.359)	(4.077)	(3.801)
TOTAL ASSETS EMPLOYED	127.046	130.977	130.250	129.737
Taxpayers' and Others' Equity				
Non Controlling interest (was Minority Interest)		0.000		
Taxpayers Equity				
Public dividend capital	84.877	87.626	87.626	87.626
Retained Earnings (Accumulated Losses)	21.076	22.899	24.272	25.860
Charitable Funds		0.000		
Other Reserves, Total	21.093	20.452	18.352	16.252
TAXPAYERS EQUITY, TOTAL	127.046	130.977	130.249	129.737
TOTAL ASSETS EMPLOYED	127.046	130.977	130.249	129.737
	TRUE	TRUE	TRUE	TRUE
Memorandum lines				
Working Capital Facility				
Committed Working capital facility in place	10.000	10.000	10.000	10.000
Figures for PBL calculation				
Planned Borrowings for PBL		2.824	2.599	2.374
Figures for NRAF calculation				
Taxpayers' equity	127.046	130.977	130.249	129.737
Leases	0.000	0.000	0.000	0.000
Borrowings	3.795	3.539	3.283	3.027
Finanacing (for FRR calculation)	130.841	134.516	133.532	132.764
Figures for Liquidity calculation				
Cash for liquidity purposes	24.217	17.753	16.691	15.866

Homerton University Hospital NHS FT

Planned Quarterly Cash Flow Statement for HOMERTON

Appendix 2

These figures should change in line with your assumptions for future years

	Actual for Year ending 31-Mar-13	Plan for Year ending 31-Mar-14	Plan for Year ending 31-Mar-15	Plan for Year ending 31-Mar-16
Surplus/(deficit) after tax	0.299	1.823	1.373	1.588
non-cash flows in operating surplus/(deficit)				
Tax expense	0.000	0.000	0.000	0.000
Finance income/charges	0.000	0.000		
Share of profit/(loss) from equity accounted investments net of cash distributions received	0.000	0.000		
Donations & Grants received of PPE & intangible assets (not cash)	0.000	0.000		
Other operating non-cash movements	0.000	0.000		
Depreciation and amortisation, total	5.723	6.322	6.619	6.663
Impairment losses/(reversals)	3.529	0.800	1.200	1.200
Unrealised (gains)/losses on foreign currency exchange	0.000	0.000		
Gain/(loss) on disposal of property plant and equipment	0.000	0.000		
Gain/(loss) on disposal of intangible assets	0.000	0.000		
Share of profit/(loss) loss from investments	0.234	0.000		
PDC dividend expense	3.184	3.212	3.582	3.486
Other increases/(decreases) to reconcile to profit/(loss) from operations	0.521	(0.249)	(0.050)	(0.100)
Non-cash flows in operating surplus/(deficit), Total	13.191	10.085	11.351	11.249
Operating Cash flows before movements in working capital	13.490	11.908	12.724	12.837
Increase/(Decrease) in working capital				
(Increase)/decrease in inventories	(0.267)	(0.194)	0.082	0.000
(Increase)/decrease in tax receivable	0.000	0.000		
(Increase)/decrease in NHS Trade Receivables	1.253	0.313	0.257	(0.257)
(Increase)/decrease in Non NHS Trade Receivables	0.017	0.647	0.287	(0.050)
(Increase)/decrease in other related party receivables	0.000	0.000		
(Increase)/decrease in other receivables	(1.102)	0.446	0.263	0.100
(Increase)/decrease in accrued income	1.432	0.030	(0.060)	(0.040)
(Increase)/decrease in other financial assets		0.000		
(Increase)/decrease in prepayments	0.363	(0.030)	0.020	(0.003)
(Increase)/decrease in Other assets (non chartable assets)	0.000	0.000		
Increase/(decrease) in Deferred Income (excl. Govt Grants.)	(2.063)	(1.260)	(0.080)	(0.050)
Increase/(decrease) in Deferred Income (Govt. Grants)		0.000		
Increase/(decrease) in Current provisions	(0.212)	(0.604)	0.098	(0.050)
Increase/(decrease) in post-employment benefit obligations	0.000	0.000		
Increase/(decrease) in tax payable	0.382	0.000	(0.006)	(0.080)
Increase/(decrease) in Trade Creditors	(4.414)	(0.206)	0.000	0.000
Increase/(decrease) in Other Creditors	0.671	(0.067)	(0.070)	0.100
Increase/(decrease) in accruals	1.853	0.328	0.000	0.000
Increase/(decrease) in other Financial liabilities	0.077	(0.241)	0.000	0.000
Increase/(decrease) in Other liabilities (non charitable assets)		0.000		
Increase/(Decrease) in working capital, Total	(2.010)	(0.839)	0.792	(0.330)
Increase/(Decrease) in Non-current Provisions		(0.033)	(0.026)	(0.020)
Net cash inflow/(outflow) from operating activities	11.480	11.036	13.490	12.487
Net cash inflow/(outflow) from investing activities				
Property - new land, buildings or dwellings	(2.218)	0.000	(1.500)	0.000
Property - maintenance expenditure	(2.441)	(9.882)	(3.784)	(5.300)
Plant and equipment - Information Technology	(0.961)	(0.740)	(0.770)	(0.700)
Plant and equipment - Other	(3.632)	(4.304)	(4.000)	(4.000)
Property, plant and equipment - other expenditure	0.000	0.000	0.000	0.000
Proceeds on disposal of property, plant and equipment	0.000	0.000	0.000	0.000
Purchase of investment property	0.000	0.000	0.000	0.000
Proceeds on disposal of investment property	0.000	0.000	0.000	0.000
Purchase of intangible assets	0.000	0.000	0.000	0.000
Proceeds on disposal of intangible assets	0.000	0.000	0.000	0.000
Expenditure on capitalised development	(0.179)	0.000	0.000	0.000
Increase/(decrease) in Capital Creditors	(0.229)	0.504	(0.156)	(0.300)
Payments for other capitalised costs		0.000		
Purchase of subsidiaries net of cash acquired		0.000		
Net bank balance acquired with subsidiaries		0.000		
Proceeds from disposal of subsidiaries net of cash disposed		0.000		
Net bank balance disposed with subsidiaries		0.000		
Purchase of associates net of cash acquired		0.000		
Net bank balance acquired with associates		0.000		
Proceeds from disposal of associates net of cash disposed		0.000		
Net bank balance disposed with associates		0.000		

Homerton University Hospital NHS FT

Planned Quarterly Cash Flow Statement for HOMERTON

Appendix 2

These figures should change in line with your assumptions for future years

	Actual for Year ending 31-Mar-13	Plan for Year ending 31-Mar-14	Plan for Year ending 31-Mar-15	Plan for Year ending 31-Mar-16
Purchase of joint ventures net of cash acquired		0.000		
Net bank balance acquired with associates		0.000		
Proceeds from disposal of joint ventures net of cash disposed		0.000		
Net bank balance disposed with joint venture		0.000		
Government grants received		0.000		
Purchase of investments & deposits made	(26.672)	0.002		(0.005)
Proceeds on disposal of investments & withdrawals	26.682	0.000		
Other cash flows from investing activities		0.000		
Net cash inflow/(outflow) from investing activities, Total	(9.650)	(14.420)	(10.210)	(10.305)
Net cash inflow/(outflow) before financing	1.830	(3.384)	3.280	2.182
Net cash inflow/(outflow) from financing activities				
Public Dividend Capital received	0.777	0.000		
Public Dividend Capital repaid	0.000	0.000		
PDC Dividends paid	(3.143)	(3.110)	(3.582)	(3.486)
Interest (paid) on bridging loans	0.000	0.000		
Interest (paid) on commercial loans	0.000	0.000		
Interest (paid) on non-commercial loans	(0.132)	0.000		
Interest (paid) on bank overdrafts		0.000		
Interest element of finance lease rental payments - <i>other</i>		0.000		
Interest element of finance lease rental payments - <i>On-balance sheet PFI</i>		0.000		
Capital element of finance lease rental payments - <i>other</i>		0.000		
Capital element of finance lease rental payments - <i>On-balance sheet PFI</i>		0.000		
Interest received on cash and cash equivalents		0.000		
Movement in Other grants/Capital received		0.000		
Donations received in cash		0.000		
Drawdown of bridging loans		0.000		
Repayment of bridging loans		0.000		
Drawdown of non-commercial loans		0.000		
Repayment of non-commercial loans	(0.226)	(0.226)	(0.226)	(0.226)
Drawdown of commercial loans		0.000		
Repayment of commercial loans		0.000		
(Increase)/decrease in non-current receivables		0.000		
Increase/(decrease) in non-current payables		0.000		
Other cash flows from financing activities	(0.031)	(0.031)	(0.031)	(0.031)
Net cash inflow/(outflow) from financing activities, Total	(2.755)	(3.367)	(3.839)	(3.743)
Net increase/(decrease) in cash	(0.925)	(6.751)	(0.559)	(1.561)
Opening cash	30.532	29.607	22.856	22.297
Effect of exchange rates		0.000		
Closing cash	29.607	22.856	22.297	20.736
<i>Closing cash from SoFP</i>	29.607	22.860	22.297	20.737
<i>Variance</i>	0.000	(0.004)	(0.000)	(0.001)
	TRUE	TRUE	TRUE	TRUE
Opening Cash and Cash equivalents		29.622	22.867	22.312
Net increase/(decrease) in cash & cash equivalents		(6.753)	(0.559)	(1.556)
Closing Cash and Cash equivalents		22.867	22.312	20.756
Closing Cash and Cash equivalents from SP		22.870	22.312	20.757
Variance		-0.004	0.000	-0.001
		TRUE	TRUE	TRUE
MEMORANDUM lines				
Debt Capital repayments		-0.226	-0.226	-0.226
Drawdown / (Repayment) of overdraft		0.000	0.000	0.000
Drawdown / (Repayment) of working capital facility		0.000	0.500	0.048
Sale / (Purchase) of current asset investments		0.002	0.000	-0.005
Change in Current Receivables		1.406	0.807	-0.207
Change in Current Payables		-0.273	-0.076	0.020
Capital expenditure (cash basis)		-14.422	-10.210	-10.300
Asset sale proceeds		0.000	0.000	0.000
Net interest		0.000	0.000	0.000
Movement in loans		-0.226	-0.226	-0.226
Capital expenditure (accruals basis)		-14.926	-10.054	-10.000

Homerton University Hospital NHS FT
2014 (and 2015, 2016) Plan for HOMERTON

Summary of key assumptions

Staff Numbers (Avg WTEs)		WTEs 2012/13	WTEs 2013/14		WTEs 2014/15		WTEs 2015/16	
New	Clinical	WTEs	2,612.1		2,683.5	2.73%	2,673.5	-0.37%
New	Non-Clinical	WTEs	915.1		930.4	1.67%	850.2	-8.62%
New	Permanent Staff	WTEs	3,448.8		3,540.4	2.65%	3,450.2	-2.55%
New	Temporary, Agency, Locum	WTEs	78.3		73.5	-6.15%	73.5	-0.03%
Ambulance overall revenue change YoY			from 2012/13 to 2013/14		from 2013/14 to 2014/15		From 2014/15 to 2015/16	
New	A&E			0.00%		0.00%		0.00%
New	PTS from PCTs			0.00%		0.00%		0.00%
New	PTS not from PCTs			0.00%		0.00%		0.00%
New	Other			0.00%		0.00%		0.00%
MH Revenue overall revenue change YoY			from 2012/13 to 2013/14		from 2013/14 to 2014/15		From 2014/15 to 2015/16	
New	High Cost Low Volume Activity Income			0.00%		0.00%		0.00%
New	Short term episodic treatment Income			0.00%		0.00%		0.00%
New	Block Contract 1			0.00%		0.00%		0.00%
New	Block Contract 2			0.00%		0.00%		0.00%
New	Block Contract 3			0.00%		0.00%		0.00%
New	Block Contract 4			0.00%		0.00%		0.00%
New	Clinical Partnerships (incl. S31 agreements)			0.00%		0.00%		0.00%
New	Clinical income for Secondary Commissioning			0.00%		0.00%		0.00%
Acute contracted revenue change due to activity change (volume) YoY			from 2012/13 to 2013/14		from 2013/14 to 2014/15		From 2014/15 to 2015/16	
New	High Cost Low Volume Activity Income		£m	0.000		0.000		0.000
New	Short term episodic treatment Income		£m	0.000		0.000		0.000
New	Block Contract 1		£m	0.000		0.000		0.000
New	Block Contract 2		£m	0.000		0.000		0.000
New	Block Contract 3		£m	0.000		0.000		0.000
New	Block Contract 4		£m	0.000		0.000		0.000
New	Clinical Partnerships (incl. S31 agreements)		£m	0.000		0.000		0.000
New	Clinical income for Secondary Commissioning		£m	0.000		0.000		0.000
Acute Activity			2012/13	2013/14		2014/15		2015/16
New	Elective	Spells	3,773	3,697	-2.01%	3,784	2.35%	3,825
New	Elective Day Cases (Planned same day)	Spells	14,718	14,982	1.79%	15,418	2.91%	15,775
New	Non elective	Spells	19,346	19,857	2.64%	20,310	2.28%	20,647
New	Outpatient	Attendances	260,265	247,102	-5.06%	255,889	3.56%	258,128
New	A&E	Attendances	82,581	82,996	0.50%	83,262	0.32%	83,681
New	Other NHS	Number	1,113,873	1,120,094	0.56%	1,161,074	3.66%	1,185,078
Acute Tariff Overall revenue change YoY			from 2012/13 to 2013/14		from 2013/14 to 2014/15		From 2014/15 to 2015/16	
New	Elective			5.38%		1.15%		-0.28%
New	Elective Day Cases (Planned same day)			0.13%		1.87%		1.05%
New	Non elective			-39.65%		1.40%		0.46%
New	Outpatient			-17.39%		2.68%		0.31%
New	A&E			-0.01%		-0.73%		-0.79%
New	Other NHS			0.00%		8.11%		1.67%
Acute contracted activity uplift/downshift (volume) Revenue YoY			from 2012/13 to 2013/14		from 2013/14 to 2014/15		From 2014/15 to 2015/16	
New	Elective		£m	(0.505)		0.000		0.000
New	Elective Day Cases (Planned same day)		£m	0.165		0.000		0.000
New	Non elective		£m	(18.011)		0.018		0.013
New	Outpatient		£m	2.669		0.000		0.000
New	A&E		£m	0.117		0.000		0.000
New	Other NHS		£m	16.399		0.000		0.000
Acute additional forecast activity (not contracted) YoY			from 2012/13 to 2013/14		from 2013/14 to 2014/15		From 2014/15 to 2015/16	
New	Elective		£m	0.000		0.229		0.109
New	Elective Day Cases (Planned same day)		£m	0.000		0.366		0.295
New	Non elective		£m	(1.547)		0.748		0.558
New	Outpatient		£m	0.000		1.236		0.510
New	A&E		£m	0.000		0.033		0.051
New	Other NHS		£m	2.672		1.677		0.919
Cost increase YoY assumptions			from 2012/13 to 2013/14		from 2013/14 to 2014/15		From 2014/15 to 2015/16	
New	Pay Cost inflation			2.00%		2.00%		2.00%
New	Drug Price inflation			5.00%		5.00%		5.00%
New	Clininical supplies expense inflation			2.50%		2.50%		2.50%
New	Non-clinical supplies expense inflation			2.50%		2.50%		2.50%
New	Misc Other operating expense inflation			2.50%		2.50%		2.50%
Impact of CPIs and revenue generation			2013/14		2014/15		2015/16	
New	Revenue Generation (gross)		£m	3.039		0.000		0.000
New	Expenses of Revenue Generation		£m	(0.894)		0.000		0.000
New	CIPs		£m	8.169		10.000		10.000
Impact of service developments			2013/14		2014/15		2015/16	
New	Revenue		£m	2.288		1.628		0.300
New	Expenses		£m	(1.895)		(1.228)		(0.300)
Contingency present in plan assumptions			2013/14		2014/15		2015/16	
New	Pay		£m	(1.419)		(0.918)		0.000
New	Drugs		£m	0.000		0.000		0.000
New	Clinical Supplies		£m	0.000		(1.200)		(1.825)
New	Non-Clinical Supplies		£m	(0.186)		(0.527)		(0.405)
New	Misc Other Operating expenses		£m	0.000		0.000		0.000

High level summary of financial plan of Homerton University Hospital

Financial Summary		2012/13	2013/14	2014/15	2015/16
£m		Actuals	Plan	Plan	Plan
Operating Revenue for EBITDA		255.6	256.1	257.3	256.5
Employee Expenses		(167.2)	(173.5)	(175.5)	(173.8)
Drugs		(12.0)	(12.4)	(13.0)	(13.7)
PFI operating expenses		0.0	0.0	0.0	0.0
Other costs		(63.5)	(57.8)	(55.8)	(55.8)
EBITDA		12.8	12.3	12.9	13.1
Donations of PPE & intangible assets		0.0	0.0	0.0	0.0
Depreciation and amortisation		(5.7)	(6.3)	(6.6)	(6.7)
Impairment Losses (Reversals) net (on non-PFI assets)		(3.5)	(0.8)	(1.2)	(1.2)
Impairment Losses (Reversals) net on PFI assets		0.0	0.0	0.0	0.0
Restructuring Costs		0.0	0.0	0.0	0.0
Operating Surplus		3.6	5.2	5.1	5.2
Net interest		0.0	(0.2)	(0.2)	(0.2)
Other Non-Operating items		(6.8)	(8.4)	(8.7)	(8.7)
Net Surplus / (Deficit)		0.3	1.8	1.4	1.6
EBITDA % Income	%	5.0%	4.8%	5.0%	5.1%
CIP% of Op.Exp. less PFI Exp.	%	1.6%	3.2%	3.9%	3.9%
Pay CIPs as % Pay Costs	%	1.3%	2.9%	3.7%	3.8%
Net Surplus / (Deficit)		0.3	1.8	1.4	1.6
Change in working capital		(2.0)	(0.8)	0.8	(0.3)
Non cash I&E items		13.2	10.1	11.4	11.2
Cashflow from operations		11.5	11.1	13.5	12.5
Cashflow from investing activities		(9.7)	(14.4)	(10.2)	(10.3)
Cashflow before financing		1.8	(3.4)	3.3	2.2
Cashflow from financing activities		(2.8)	(3.4)	(3.8)	(3.7)
Net increase/(decrease) in cash		(0.9)	(6.7)	(0.5)	(1.5)
Cash at period end		29.6	22.9	22.3	20.7
Cash and Cash equivalents at period end		29.6	22.9	22.3	20.8

Detailed Financial Summary		2012/13	2013/14	2014/15	2015/16
£m		Actuals	Plan	Plan	Plan
Community					
Co Cost & volume contract revenue		0.0	0.0	0.0	0.0
Co Block contract revenue		46.8	46.1	44.9	43.9
Ambulance					
Am Cost & volume contract revenue		0.0	0.0	0.0	0.0
Am Block contract revenue		0.0	0.0	0.0	0.0
Am Other clinical MS revenue		0.0	0.0	0.0	0.0
Mental Health					
Mh Cost & volume contract revenue		0.0	0.0	0.0	0.0
Mh Block contract revenue		0.0	0.0	0.0	0.0
Mh Clinical partnership (s31) revenue		0.0	0.0	0.0	0.0
Mh Secondary commissioning revenue		0.0	0.0	0.0	0.0
Mh Other clinical MS revenue		0.0	0.0	0.0	0.0
Acute					
Ac Elective revenue		23.2	23.8	24.1	24.2
Ac Non-Elective revenue		50.2	31.0	31.4	31.5
Ac Outpatient revenue		34.6	37.5	38.3	38.3
Ac A&E revenue		10.2	10.2	10.1	10.0
Ac other revenue		56.5	80.3	82.9	83.1
Private patient revenue		0.5	0.6	0.6	0.6
Grants and donations in cash		0.4	0.0	0.0	0.0
Other operating revenues		33.2	26.7	24.9	24.7
Total operating revenue for EBITDA		255.6	256.1	257.3	256.5
Grants and donations of PPE and intangible assets		0.0	0.0	0.0	0.0
Total operating revenue		255.6	256.1	257.3	256.5
Employee Expenses		(167.2)	(173.5)	(175.5)	(173.8)
Drugs expense		(12.0)	(12.4)	(13.0)	(13.7)
Supplies (clinical & non-clinical)		(60.4)	(56.2)	(55.8)	(55.8)
PFI expenses		0.0	0.0	0.0	0.0
Other expenses		(3.1)	(1.6)	0.0	0.0
Total operating expenses within EBITDA		(242.8)	(243.8)	(244.3)	(243.3)
EBITDA		12.8	12.3	12.9	13.1
Depreciation and amortisation		(5.7)	(6.3)	(6.6)	(6.7)
Impairments & Restructuring		0.0	0.0	0.0	0.0
Total operating expenses		(254.2)	(256.4)	(257.6)	(256.7)
Operating Surplus (Deficit)		1.4	(0.3)	(0.3)	(0.2)
Gain (loss) on asset disposal		(0.1)	0.0	0.0	0.0
Gain/(loss) from transfer by absorbtion		0.0	0.0	0.0	0.0
Net interest		0.0	(0.2)	(0.2)	(0.2)
Taxation		0.0	0.0	0.0	0.0
PDC dividend		(3.2)	(3.2)	(3.6)	(3.5)
Other non-operating items		(3.5)	(0.8)	(1.2)	(1.2)
Net Surplus / (Deficit)		0.3	1.8	1.4	1.6
EBITDA % of Op. revenue		5.0%	4.8%	5.0%	5.1%
EBITDA		12.8	12.3	12.9	13.1
Change in Current Receivables		0.2	1.4	0.8	(0.2)
Change in Current Payables		(3.4)	(0.3)	(0.1)	0.0
Other changes in WC		1.2	(2.0)	0.1	(0.1)
Other non-cash items		0.7	(0.5)	(0.2)	(0.3)
Cashflow from operating activities		11.5	11.0	13.5	12.5
Capital expenditure (accruals basis)		(6.0)	(10.1)	(6.2)	(6.3)
Asset sale proceeds		0.0	0.0	0.0	0.0
other Investing cash flows		(3.6)	(4.3)	(4.0)	(4.0)
Cashflow before financing		1.8	(3.4)	3.3	2.2
Net interest		(0.1)	0.0	0.0	0.0
PDC dividends (paid)		(3.1)	(3.1)	(3.6)	(3.5)
Movement in loans		(0.2)	(0.2)	(0.2)	(0.2)
PDC received/(repaid)		0.8	0.0	0.0	0.0
Donations received in cash		0.0	0.0	0.0	0.0
other financing cashflows		(0.0)	(0.0)	(0.0)	(0.0)
Net cash inflow (outflow)		(0.9)	(6.8)	(0.6)	(1.6)
Cash at Y/E		29.6	22.9	22.3	20.7
Cash and Cash equivalents at Y/E		29.6	22.9	22.3	20.8
Non Safe Harbour Investments at Y/E		0.0	0.0	0.0	0.0

Continuity of Service Shadow Risk Ratings (pilot indicators for 2013/14)

Debt Service Cover

PDC dividend expense	from SoCI
Interest Expense on Overdrafts and Working Capital Facilities	from SoCI
Interest Expense on Bridging loans	from SoCI
Interest Expense on Non-commercial borrowings	from SoCI
Interest Expense on Commercial borrowings	from SoCI
Interest Expense on Finance leases (non-PFI)	from SoCI
Interest Expense on PFI leases & liabilities	from SoCI
Other Finance Costs	from SoCI
Non-Operating PFI costs (eg contingent rent)	from SoCI
Public Dividend Capital repaid	from SoCF
Repayment of bridging loans	from SoCF
Repayment of non-commercial loans	from SoCF
Repayment of commercial loans	from SoCF
Capital element of finance lease rental payments - On-balance sheet	from SoCF
Capital element of finance lease rental payments - other	from SoCF

Revenue available for Debt Service
Debt Service
Debt Service Cover metric
Debt Service Cover rating

Liquidity

Cash for CoS liquidity purposes	from SoFP
Operating Expenses within EBITDA, Total	from SoCI
Liquidity metric	
Liquidity rating	

Continuity of Service Risk Rating

Historic Year to 31-Mar-13	Plan for Year to 30-Jun-13	Plan for Year to 30-Sep-13	Plan for Year to 31-Dec-13	Plan for Year to 31-Mar-14	Plan for Year to 31-Mar-15	Plan for Year to 31-Mar-16
(3.184)	(0.803)	(1.606)	(2.409)	(3.212)	(3.582)	(3.486)
-	-	-	-	-	-	-
-	-	-	-	-	-	-
(0.174)	(0.044)	(0.087)	(0.130)	(0.174)	(0.174)	(0.174)
-	-	-	-	-	-	-
-	-	-	-	-	-	-
-	-	-	-	-	-	-
(0.016)	-	-	-	-	-	-
-	-	-	-	-	-	-
-	-	-	-	-	-	-
-	-	-	-	-	-	-
(0.226)	-	(0.113)	(0.113)	(0.226)	(0.226)	(0.226)
-	-	-	-	-	-	-
-	-	-	-	-	-	-
-	-	-	-	-	-	-
-3.600	-0.847	-1.806	-2.652	-3.612	-3.982	-3.886
13.013	2.613	6.075	8.954	12.330	12.948	13.111
-3.600	-0.847	-1.806	-2.652	-3.612	-3.982	-3.886
3.61x	3.09x	3.36x	3.38x	3.41x	3.25x	3.37x
4	4	4	4	4	4	4

14.217	13.248	11.175	8.062	7.753	6.691	5.866
-242.768	-60.619	-121.419	-182.665	-243.801	-244.317	-243.346
21.1	19.7	16.6	11.9	11.4	9.9	8.7
4	4	4	4	4	4	4

4	4	4	4	4	4	4
---	---	---	---	---	---	---

key to scoring

Debt Service Cover		50%	
4	3	2	1
2.5	1.75	1.25	<1.25

key to scoring

Liquidity		50%	
4	3	2	1
-2	-7	-12	<-12

Risk Ratings based on Annual Planning return from HOMERTON

		Historic Year to 31-Mar-13	Forecast YTD to 30-Jun-13	Forecast YTD to 30-Sep-13	Forecast YTD to 31-Dec-13	Forecast Year to 31-Mar-14	Forecast Year to 31-Mar-15	Forecast Year to 31-Mar-16
Underlying performance								
EBITDA YTD from SoCI		12.807	2.613	6.075	8.954	12.330	12.948	13.111
Operating Income YTD from SoCI		255.575	63.232	127.494	191.618	256.132	257.265	256.457
EBITDA Margin metric		5.0%	4.1%	4.8%	4.7%	4.8%	5.0%	5.1%
EBITDA Margin rating		3	2	2	2	2	3	3
Achievement of plan								
Actual EBITDA 2012-13 from SoCI		12.807						
Planned EBITDA 2012-13 (original plan or assessment figure)		12.042						
EBITDA % of plan achived metric		106.4%	106.4%	106.4%	106.4%	106.4%	106.4%	106.4%
EBITDA % of plan achived rating		5	5	5	5	5	5	5
Financial Efficiency								
Net return after financing costs, YTD from SoCI		3.916	0.237	1.322	1.825	2.623	2.573	2.788
Opening Financing		129.775	130.841	130.841	130.841	130.841	134.516	133.532
Closing Financing		130.841	134.385	135.328	135.831	134.516	133.532	132.764
Net return after Financing metric		3.0%	0.7%	2.0%	1.8%	2.0%	1.9%	2.1%
Net return after financing rating		5	3	3	3	3	3	4
Surplus YTD from SoCI		0.299	0.237	1.322	1.825	1.823	1.373	1.588
Gain/(loss) on asset disposals from SoCI		(0.088)	-	-	-	-	-	-
Gain/(loss) from transfer by absorbtion		-	-	-	-	-	-	-
I & R (Impairments & restructuring) expenses YTD from SoCI		(3.529)	-	-	-	(0.800)	(1.200)	(1.200)
Operating Income YTD from IS		255.575	63.232	127.494	191.618	256.132	257.265	256.457
IS Surplus margin metric		1.5%	0.4%	1.0%	1.0%	1.0%	1.0%	1.1%
IS Surplus margin rating		3	2	3	2	3	3	3
Financial Efficiency rating		4	3	3	3	3	3	4
Liquidity								
Cash for liquidity purposes from SoFP		24.217	23.248	21.175	18.062	17.753	16.691	15.866
Operating expenditure YTD from SoCI		242.768	60.619	121.419	182.665	243.801	244.317	243.346
WCF in terms of Operating Expenditure YTD		14.8	14.8	14.8	14.8	14.8	14.7	14.8
Liquidity days metric (WCF limited to 30 days)		35.9	34.5	31.4	26.7	26.2	24.6	23.5
Liquidity rating		4	4	4	4	4	3	3
Weighted Average Rating		3.85	3.00	3.20	3.00	3.20	3.20	3.40
Overriding rules								
3 Return submitted on time		YES						
3 Return submitted complete and correct		YES						
2 PDC dividend paid in full				FALSE		FALSE	FALSE	FALSE
3 Year 2 OR Year 3 deficit excluding I & R expenses		NO						
2 Year 2 AND Year 3 deficit excluding I & R expenses		NO						
2 Lowest ranked metric a '1'?			FALSE	FALSE	FALSE	FALSE	FALSE	FALSE
3 One financial criteria '1' or '2'			FALSE	TRUE	3	TRUE	3	FALSE
2 Two financial criteria '1' or '2'			FALSE	FALSE	FALSE	FALSE	FALSE	FALSE
1 Two financial criteria at '1'			FALSE	FALSE	FALSE	FALSE	FALSE	FALSE
2 Unplanned breach of PBC ratios		NO						
4 Less than 1 year as an Foundation Trust			FALSE	FALSE	FALSE	FALSE	FALSE	FALSE
Limit due to overriding rules		0	3	3	3	3	0	0
Financial Risk Rating		4	3	3	3	3	3	3

The number above is NOT necessarily the same as your Q4 FY1213 FRR because it is calculated on the basis of the 13-14 Compliance Framework

Financial Summary	Previous YE	Current Quarter			YTD	FY		
£m	Actual	Plan	Actual	Variance	Plan	Actual	Variance	Plan
Operating Revenue for EBITDA	255.6	64.3	63.6	(0.6)	127.5	129.3	1.8	256.1
Employee Expenses	(167.2)	(42.9)	(44.0)	(1.1)	(86.1)	(87.8)	(1.7)	(173.5)
Drugs	(12.0)	(3.1)	(3.1)	0.0	(6.3)	(6.2)	0.1	(12.4)
PFI operating expenses	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other costs	(63.5)	(14.8)	(14.1)	0.7	(29.1)	(30.0)	(0.9)	(57.8)
Clinical supplies	(18.8)	(4.2)	(4.4)	(0.2)	(8.4)	(8.9)	(0.5)	(16.7)
Decrease (increase) in inventories of finished goods & WIP	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Vehicle Fuel costs (ambulance trusts)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Non-clinical supplies	(41.6)	(10.2)	(9.1)	1.1	(19.9)	(18.5)	1.3	(39.5)
Cost of Secondary Commissioning of mandatory services	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Research & Development expense	(0.3)	(0.0)	(0.2)	(0.2)	(0.0)	(0.3)	(0.2)	(0.1)
Education and training expense	(1.0)	(0.2)	(0.2)	0.1	(0.5)	(0.4)	0.1	(1.0)
Misc. other Operating expenses	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBITDA	12.8	3.5	2.5	(0.9)	6.1	5.4	(0.7)	12.3
Donations of PPE & intangible assets	0.0	0.0	1.0	1.0	0.0	1.0	1.0	0.0
Depreciation and amortisation	(5.7)	(1.5)	(1.5)	0.0	(3.1)	(3.0)	0.0	(6.3)
Impairment Losses (Reversals) net (on non-PFI assets)	(3.5)	0.0	0.0	0.0	0.0	0.0	0.0	(0.8)
Impairment Losses (Reversals) net on PFI assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Restructuring Costs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Operating Surplus	3.6	1.9	2.0	0.1	3.0	3.3	0.3	5.2
Net Interest	0.0	(0.0)	(0.0)	0.0	(0.1)	(0.0)	0.0	(0.2)
Interest Income	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Interest Expense on Overdrafts and Working Capital Facilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Interest Expense on Bridging loans	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Interest Expense on Non-commercial borrowings	(0.2)	(0.0)	(0.0)	(0.0)	(0.1)	(0.1)	0.0	(0.2)
Interest Expense on Commercial borrowings	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Interest Expense on Finance leases (non-PFI)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Interest Expense on PFI leases & liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Operating items	(3.3)	(0.8)	(1.0)	(0.2)	(1.6)	(1.8)	(0.2)	(3.2)
Gain (Loss) on Financial Instruments Designated as Cash Flow Hedges	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Gain (Loss) on Derecognition of Available-for-Sale Financial Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Gain (Loss) on Derecognition of Non-Current Assets Not Held for Sale, Total	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Gain (Loss) from investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Dividend Income	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Share of profit (loss) from equity accounted Associates, Joint Ventures, Total	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Operating income, Total	(0.1)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Finance Costs	(0.0)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
PDC dividend expense	(3.2)	(0.8)	(1.0)	(0.2)	(1.6)	(1.8)	(0.2)	(3.2)
PFI Contingent Rent	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Operating expenses (incl. Misc)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Income Tax (expense)/ income	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net Surplus / (Deficit)	0.3	1.1	1.0	(0.1)	1.3	1.5	0.2	1.8
EBITDA % Income	5.0%	5.4%	4.0%	-1.4%	4.8%	4.2%	-0.6%	4.8%
CIP% of Op.Exp. less PFI Exp.	1.6%	3.1%	2.5%	-0.6%	2.9%	2.3%	-0.6%	3.2%
Pay CIPs as % Pay Costs	-1.3%	-2.9%	-2.4%	0.6%	-2.9%	-2.3%	0.6%	-2.9%
Net Surplus / (Deficit)	0.3	1.1	1.0	(0.1)	1.3	1.5	0.2	1.8
Change in working capital	(2.0)	0.1	5.3	5.2	(2.8)	(10.4)	(7.6)	(0.8)
(Increase)/decrease in inventories	(0.3)	0.0	0.0	0.0	0.0	0.0	0.0	(0.2)
(Increase)/decrease in tax receivable	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
(Increase)/decrease in NHS Trade Receivables	1.3	1.6	(0.2)	(1.8)	(1.2)	(10.3)	(9.0)	0.3
(Increase)/decrease in Non NHS Trade Receivables	0.0	0.3	(0.4)	(0.7)	0.3	0.2	(0.1)	0.6
(Increase)/decrease in other related party receivables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
(Increase)/decrease in other receivables	(1.1)	0.0	(0.5)	(0.5)	0.4	(0.1)	(0.5)	0.4
(Increase)/decrease in accrued income	1.4	0.0	6.7	6.7	0.0	2.0	2.0	0.0
(Increase)/decrease in other financial assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
(Increase)/decrease in prepayments	0.4	(0.3)	(0.1)	0.1	(0.5)	(1.2)	(0.6)	(0.0)
(Increase)/decrease in Other assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Increase/(decrease) in Deferred Income (excl. Donated Assets)	(2.1)	(0.2)	(0.5)	(0.3)	(0.3)	(0.9)	(0.6)	(1.3)
Increase/(decrease) in Deferred Income (Donated Assets)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Increase/(decrease) in Current provisions	(0.2)	(0.1)	(0.0)	0.0	(0.1)	(0.0)	0.0	(0.6)
Increase/(decrease) in post-employment benefit obligations	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Increase/(decrease) in tax payable	0.4	0.0	0.2	0.1	(0.2)	0.3	0.5	0.0
Increase/(decrease) in Trade Creditors	(4.4)	(0.3)	2.5	2.7	(0.6)	1.7	2.2	(0.2)
Increase/(decrease) in Other Creditors	0.7	(0.1)	0.5	0.6	0.1	0.3	0.3	(0.1)
Increase/(decrease) in accruals	1.9	(1.1)	(2.4)	(1.3)	(0.6)	(2.0)	(1.4)	0.3
Increase/(decrease) in other Financial liabilities	0.1	0.0	(0.4)	(0.4)	(0.2)	(0.4)	(0.2)	(0.2)
Increase/(decrease) in Other liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Increase/(decrease) in Non Current provisions	0.0	0.0	0.0	0.0	0.0	0.0	0.0	(0.0)
Non cash I&E items	13.2	2.3	2.7	0.4	4.4	6.6	2.1	10.1
Tax expense/(refund)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Finance (income)/charges	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Share of (profit)/loss from equity accounted investments net of cash distributions received	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Donations & Grants received of PPE & intangible assets (non cash)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other operating non-cash (revenues)/expenses	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Depreciation and amortisation, total	5.7	1.5	1.5	(0.0)	3.1	3.0	(0.0)	6.3
Impairment losses/(reversals)	3.5	0.0	0.0	0.0	0.0	0.0	0.0	0.8
Unrealised (gains)/losses on foreign currency exchange	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
(Gain)/loss on disposal of property plant and equipment	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
(Gain)/loss on disposal of intangible assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Share of (profit)/loss loss from investments	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0
PDC dividend expense	3.2	0.8	1.0	0.2	1.6	1.8	0.2	3.2
Other increases/(decreases) to reconcile to profit/(loss) from operations	0.5	(0.0)	0.2	0.3	(0.2)	1.8	2.0	(0.2)
Cashflow from operations	11.5	3.4	9.0	5.6	3.0	(2.3)	(5.3)	11.0
Cashflow from investing activities	(9.7)	(4.3)	(1.6)	2.7	(6.9)	(6.5)	0.3	(14.4)
Property, plant and equipment - maintenance expenditure	(2.4)	(3.2)	(2.0)	1.2	(5.7)	(3.8)	2.0	(9.9)
Property, plant and equipment - non-maintenance expenditure	(2.2)	0.0	(0.0)	(0.0)	0.0	(0.1)	(0.1)	0.0
Plant and equipment - Information Technology	(1.0)	(0.2)	(0.0)	0.2	(0.2)	(0.0)	0.2	(0.7)
Plant and equipment - Other	(3.6)	(1.2)	(3.6)	(2.4)	(1.3)	(4.5)	(3.1)	(4.3)
Property, plant and equipment - other expenditure	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Proceeds on disposal of property, plant and equipment	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Purchase of investment property	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Proceeds on disposal of investment property	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Purchase of intangible assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Proceeds on disposal of intangible assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Expenditure on capitalised development	(0.2)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Increase/(decrease) in Capital Creditors	(0.2)	0.3	1.6	1.3	0.4	1.9	1.4	0.5
Payments for other capitalised costs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Purchase of subsidiaries net of cash acquired	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net bank balance acquired with subsidiaries	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Proceeds from disposal of subsidiaries net of cash disposed	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net bank balance disposed with subsidiaries	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Purchase of associates net of cash acquired	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net bank balance acquired with associates	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Proceeds from disposal of associates net of cash disposed	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net bank balance disposed with associates	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Purchase of joint ventures net of cash acquired	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net bank balance acquired with associates	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Proceeds from disposal of joint ventures net of cash disposed	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net bank balance disposed with joint venture	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Government grants received	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deposits and investments made	(26.7)	0.0	0.0	0.0	0.0	(2.5)	(2.5)	0.0
Deposits and investments liquidated	26.7	0.0	2.4	2.4	0.0	2.4	2.4	0.0
Other cash flows from investing activities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cashflow before financing	1.8	(0.9)	7.5	8.3	(3.9)	(8.8)	(5.0)	(3.4)
Cashflow from financing activities	(2.8)	(1.6)	1.2	2.8	(1.6)	1.2	2.8	(3.4)
Public Dividend Capital received	0.8	0.0	3.0	3.0	0.0	3.0	3.0	0.0
Public Dividend Capital repaid	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
PDC Dividends paid	(3.1)	(1.5)	(1.7)	(0.2)	(1.5)	(1.7)	(0.2)	(3.1)
Interest (paid) on bridging loans	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Interest (paid) on commercial loans	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Interest (paid) on non-commercial loans	(0.1)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Interest (paid) on overdraft and working capital facility	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Interest element of finance lease rental payments - other	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Interest element of finance lease rental payments - On-balance sheet PFI	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital element of finance lease rental payments - other	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital element of finance lease rental payments - On-balance sheet PFI	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Interest received on cash and cash equivalents	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net increase/(decrease) in cash	(0.9)	(2.5)	8.6	11.1	(5.5)	(7.7)	(2.1)	(6.8)
Cash at period end	29.6	24.1	21.9	(2.2)	24.1	21.9	(2.2)	22.9
Cash and Cash equivalents at period end	29.6	24.1	22.0	(2.1)	24.1	22.0	(2.1)	22.9

Detailed Financial Summary £m	Previous YE	Current Quarter			YTD			FY
	Actual	Plan	Actual	Variance	Plan	Actual	Variance	Plan
Community								
Co Cost & volume contract revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Co Block contract revenue	46.8	11.5	11.6	0.1	23.0	23.2	0.1	46.1
Ambulance								
Am Cost & volume contract revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Am Block contract revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Am Other clinical MS revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Mental Health								
Mh Cost & volume contract revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Mh Block contract revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Mh Clinical partnership (s31) revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Mh Secondary commissioning revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Mh Other clinical MS revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Acute								
Ac Elective revenue	23.2	5.9	5.6	(0.3)	11.7	11.5	(0.2)	23.8
Ac Non-Elective revenue	50.2	7.6	7.0	(0.6)	15.0	14.1	(0.9)	31.0
Ac Outpatient revenue	34.6	9.4	9.5	0.1	18.7	22.0	3.2	37.5
Ac A&E revenue	10.2	2.5	2.5	0.0	5.1	5.2	0.0	10.2
Ac other revenue	56.5	20.3	19.6	(0.7)	40.3	38.7	(1.7)	80.3
Private patient revenue	0.5	0.2	0.2	0.1	0.3	0.4	0.1	0.6
Grants and donations in cash	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other operating revenues	33.2	6.8	7.5	0.7	13.2	14.3	1.1	26.7
Total operating revenue for EBITDA	255.6	64.3	63.6	(0.6)	127.5	129.3	1.8	256.1
Grants and donations of PPE and intangible assets	0.0	0.0	1.0	1.0	0.0	1.0	1.0	0.0
Total operating revenue	255.6	64.3	64.6	0.4	127.5	130.3	2.8	256.1
Employee Expenses	(167.2)	(42.9)	(44.0)	(1.1)	(86.1)	(87.8)	(1.7)	(173.5)
Drugs expense	(12.0)	(3.1)	(3.1)	0.0	(6.3)	(6.2)	0.1	(12.4)
Supplies (clinical & non-clinical)	(60.4)	(14.4)	(13.5)	0.9	(28.3)	(27.4)	0.8	(56.2)
PFI expenses	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other expenses	(3.1)	(0.4)	(0.6)	(0.2)	(0.8)	(2.6)	(1.8)	(1.6)
Total operating expenses within EBITDA	(242.8)	(60.8)	(61.1)	(0.3)	(121.4)	(123.9)	(2.5)	(243.8)
EBITDA	12.8	3.5	2.5	(0.9)	6.1	5.4	(0.7)	12.3
Depreciation and amortisation	(5.7)	(1.5)	(1.5)	0.0	(3.1)	(3.0)	0.0	(6.3)
Impairments & Restructuring	(3.5)	0.0	0.0	0.0	0.0	0.0	0.0	(0.8)
Total operating expenses	(252.0)	(62.3)	(62.6)	(0.3)	(124.5)	(126.9)	(2.5)	(250.9)
Operating Surplus (Deficit)	3.6	1.9	2.0	0.1	3.0	3.3	0.3	5.2
Profit (loss) on asset disposal	(0.1)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net interest	0.0	(0.0)	(0.0)	0.0	(0.1)	(0.0)	0.0	(0.2)
Taxation	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
PDC dividend	(3.2)	(0.8)	(1.0)	(0.2)	(1.6)	(1.8)	(0.2)	(3.2)
Other non-operating items	(0.0)	0.0	1.0	1.0	(0.0)	1.0	1.0	0.0
Net Surplus / (Deficit)	0.3	1.1	1.0	(0.1)	1.3	1.5	0.2	1.8
EBITDA % of Op. revenue	5.0%	5.4%	4.0%	-1.4%	4.8%	4.2%	-0.6%	4.8%
EBITDA	12.8	3.5	2.5	(0.9)	6.1	5.4	(0.7)	12.3
Change in Current Receivables	0.2	2.0	(1.0)	(3.0)	(0.5)	(10.2)	(9.7)	1.4
Change in Current Payables	(3.4)	(0.3)	3.1	3.4	(0.7)	2.3	3.0	(0.3)
Other changes in WC	1.2	(1.6)	3.2	4.8	(1.6)	(2.5)	(0.9)	(2.0)
Change in Non Current Provisions	0.0	0.0	0.0	0.0	0.0	0.0	0.0	(0.0)
Other non-cash items	0.7	(0.1)	1.2	1.3	(0.3)	2.7	3.0	(0.4)
Cashflow from operating activities	11.5	3.4	9.0	5.6	3.0	(2.3)	(5.3)	11.0
Capital expenditure (accruals basis)	0.0	(4.6)	(5.6)	(1.0)	(7.3)	(8.4)	(1.1)	(14.9)
Asset sale proceeds	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
other Investing cash flows	(9.7)	0.3	4.1	3.7	0.4	1.8	1.4	0.5
Cashflow before financing	1.8	(0.9)	7.5	8.3	(3.9)	(8.8)	(5.0)	(3.4)
Net interest	(0.1)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
PDC dividends (paid)	(3.1)	(1.5)	(1.7)	(0.2)	(1.5)	(1.7)	(0.2)	(3.1)
Movement in loans	(0.2)	(0.1)	(0.1)	0.0	(0.1)	(0.1)	0.0	(0.2)
PDC received/(repaid)	0.8	0.0	3.0	3.0	0.0	3.0	3.0	0.0
Donations received in cash	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
other financing cashflows	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)
Net cash inflow (outflow)	(0.9)	(2.5)	8.6	11.1	(5.5)	(7.7)	(2.1)	(6.8)
Cash at period end	29.6	24.1	21.9	(2.2)	24.1	21.9	(2.2)	22.9
Cash and Cash equivalents at period end	29.6	24.1	22.0	(2.1)	24.1	22.0	(2.1)	22.9
Non Safe Harbour Investments at period end	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Name of Trust Homerton University Hospital NHS Foundation Trust **Based on year ending** 31/03/2013

Assumptions

Total Revenues £190,424,665

Surplus/(Deficit) before Interest £5,998,753

Depreciation £6,251,485

Revenues available for Debt Service £12,250,238

Dividends Paid (£3,254,000)

Total Assets Employed £118,343,153

Estimated Prudential Borrowing Limit - Tier 1 £56,150,237

Estimated Prudential Borrowing Cap - Tier 2 £94,723,478

Proposed Debt £14,392,249

Interest Rate 3.74%

Term of Borrowing 20.4

Current Risk Rating 3

Debt to Capital Ratio

Prudential Borrowing Limit

Annual Interest payable (year 1)

Annual Principal repayments

Max Annual Debt Service

Minimum Dividend Cover (min)

Minimum Interest Cover (min)

Minimum Debt Service Cover (min)

Maximum Debt Service to Revenue (max)

Complies with Prudential Borrowing Code

Current Required Covenant Ratio

Fails Prudential Borrowing Code

Debt sustainable under individual covenant tests

	Estimated PBL Tier 1 47%	Proposed Debt	TIER 1				TIER 2			
		12%	47%	60%	92%	203%	80%	139%	187%	203%
	£56,150,237	£14,392,249	£56,150,237	£70,779,738	£109,200,050	£240,542,041	£94,723,478	£164,053,972	£221,162,249	£240,542,248
	£2,099,193	£538,058	£2,099,193	£2,646,121	£4,082,476	£8,992,735	£3,541,265	£6,133,206	£8,268,216	£8,992,743
	£2,750,880	£705,097	£2,750,880	£3,467,600	£5,349,865	£11,784,496	£4,640,637	£8,037,237	£10,835,052	£11,784,506
	£4,850,073	£1,243,155	£4,850,073	£6,113,721	£9,432,341	£20,777,231	£8,181,903	£14,170,443	£19,103,268	£20,777,249
Tier 1										
1	3.12	3.60	3.12	2.95	2.51	1.00	2.68	1.88	1.22	1.00
3	5.84	22.77	5.84	4.63	3.00	1.36	3.46	2.00	1.48	1.36
2	2.53	9.85	2.53	2.00	1.30	0.59	1.50	0.86	0.64	0.59
2.5%	2.55%	0.65%	2.50%	3.20%	5.00%	10.90%	4.30%	7.40%	10.00%	10.90%